Watch AVIR. Know when insiders buy.
One email the day a filing lands. Free.
AVIR
Atea Pharmaceuticals, Inc.
5.83
+0.01 +0.17%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
45
WATCH · shorts 45
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $467.6MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$165.3MNET CASH —52W 2.82 – 6.15SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$35.1M | −$32.9M | — | -0.41 | −$37.1M | — | — | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$48M | −$45.4M | — | -0.57 | −$46.4M | — | — | Aug 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$54.9M | −$44.9M | — | -0.57 | −$28.2M | — | — | Mar 5 |
| Q3 2025 · Sep 30 | — | — | — | −$45.6M | −$42M | — | -0.53 | −$40.4M | — | — | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$41.3M | −$37.2M | — | -0.44 | −$32.9M | — | — | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$39M | −$34.3M | — | -0.40 | −$30.6M | — | — | Aug 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$39M | −$33.5M | — | -0.40 | −$30.4M | — | — | Mar 5 |
| Q3 2024 · Sep 30 | — | — | — | −$37.2M | −$31.2M | — | -0.37 | −$23M | — | — | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$46.9M | −$40.5M | — | -0.48 | −$42.2M | — | — | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$69.8M | −$63.2M | — | -0.75 | −$39.9M | — | — | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$46.6M | −$39.2M | — | -0.47 | −$21.8M | — | — | Mar 6 |
| Q3 2023 · Sep 30 | — | — | — | −$40.8M | −$33.1M | — | -0.40 | −$17.6M | — | — | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$180.9M | −$158.3M | — | -1.94 | −$132M | — | — | $25.5M | — |
| FY2024 · to Dec 31 | — | — | −$192.9M | −$168.4M | — | -2.00 | −$135.5M | — | — | $0 | — |
| FY2023 · to Dec 31 | — | — | −$164.2M | −$136M | — | -1.63 | −$85.4M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$130.7M | −$115.9M | — | -1.39 | −$121M | $1.9M | −$122.9M | — | — |
| FY2021 · to Dec 31 | $351.4M | — | $138.4M | $121.2M | 34.5% | 1.37 | −$87M | $4K | −$87M | — | — |
| FY2020 · to Dec 31 | $48.6M | — | −$11M | −$10.9M | -22.5% | -0.51 | $296.7M | $26K | $296.7M | — | — |
Every number comes from Atea Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.